With years of experience and high-end technologies in antibody development, Creative Biolabs has successfully developed a series of innovative and diversified antibody platforms to provide comprehensive and convenient anti-glycan antibody services for our worldwide customers. At present, we are capable of offering you anti-mucin antibody for multiple applications.
Mucins are large, flexible, extracellular glycoproteins with molecular weights (MW) ranging from 0.5 to 20 MDa. Both membrane-bound and secreted mucins are highly glycosylated consisting of almost 80% carbohydrates. Secreted forms appear as networks through the arrangement of monomers in homo-oligomeric structures and are mostly found at mucosal surfaces as viscoelastic gels, while the membrane-associated mucins are typical monomeric, membrane-anchored glycoproteins which do not form gels. At present, approximately 19 mucins (designated MUC) genes have been identified cloned and partially sequenced in the human. Only MUC1, MUC2, and MUC5B genes have been totally sequenced due to the large size of the central tandem repeats, which are difficult to accurately assemble.
Fig.1 Classification of human mucins and the four common mucin-type O-glycans (core-1-4). (Rodríguez, 2015)
Changes in glycosylation will influence all glycoconjugates, including the mucins. Expression changes of mucins in cancer have been identified at mucosal surfaces throughout the body and generally lead to decreased mucosal protection, loss of normal function and modified interaction with bacterial populations in normal and pathological contexts.
Immunohistological examination of mucin expression in invasive ductal carcinomas of the breast demonstrated an elevated level of MUC1 also associated with abnormal glycosylation and a range of different anti-MUC1 antibody have been employed to detect the mucin in normal breast tissues and tumors.
In gastric cancer, a wide range of biochemical and molecular biological studies have identified the involvement of MUC1-MUC6 expression and their glycosylation. Antibody probing for MUC1 reveals an association with increased expression and disease staging. Besides, strong MUC5AC levels could be associated with a good prognosis. Additionally, the mucin peptide glycan marker Galβ1-3GalNAc-Ser/Thr normally relates to a poor outcome independent of tumor stage and is also a prognostic marker in stage I tumors.
MUC5AC has been proved to be an early oncofetal marker of colon carcinogenesis. The increase in MUC1 and MUC6 is also seen in colorectal polyps and is differentially regulated in adenomas.
The expression of at least nine mucin genes has been reported in the human respiratory tract, MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC16, and MUC19.
Creative Biolabs is equipped with state-of-the-art research and manufacturing facilities and dedicated to help our clients design and prepare highly customized anti-mucin antibody using our featured services. With novel technique platform and professional experiment services, Creative Biolabs gets ready to provide you with the best antibody services. Please feel free to contact us for more details.
Reference:
